Condition (MeSH)
Keratoderma, Palmoplantar
ClinicalTrials.gov lists 17 trials for Keratoderma, Palmoplantar or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 17 trials are tagged with Keratoderma, Palmoplantar itself; the rest are tagged with a narrower condition beneath it.
When did Keratoderma, Palmoplantar trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 2 |
| 2018 | 2 |
| 2015 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Keratoderma, Palmoplantar trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Not applicable | 4 |
| Observational | 8 |
| Expanded access | 1 |
How many Keratoderma, Palmoplantar trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 8 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Keratoderma, Palmoplantar trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 2 |
| Proteocyte Diagnostics Inc. | 2 |
| Candela Corporation | 1 |
| Hope Biosciences Research Foundation | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Keratoderma, Palmoplantar? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Tapinarof | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Solution Vehicle | 2 |
| AN2690 Topical Solution, 5% | 2 |
| 1- Erlotinib | 1 |
| HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells) | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Keratoderma, Palmoplantar trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Coronary artery disease (unrelated) | 2 | 1 |
| Osteoarthritis (unrelated) | 2 | 1 |
| Pulmonary embolism (unrelated) | 2 | 2 |
| Acute myocardial infarction (unrelated) | 1 | 1 |
| Anaemia (unrelated) | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Keratoderma, Palmoplantar? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma. | European journal of human genetics : EJHG | 2015 | Yes |
| Pachyonychia congenita in pediatric patients: natural history, features, and impact. | JAMA dermatology | 2014 | Yes |
| Clinical and pathological features of pachyonychia congenita. | The journal of investigative dermatology. Symposium proceedings | 2005 | Yes |
| Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. | Cancer investigation | 2002 | Yes |
| The portrait and paper of a forgotten hero--Luca Stulli (1772-1828) and the Mal de Meleda of yesteryear: a 175-year anniversary. | The Journal of investigative dermatology | 2001 | Yes |
Showing 5 of 8 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.